The word “generic” is doing a lot of work in the coverage of this subject, and it is worth separating three things that are usually run together: a patent expiring, a regulator approving a copy, and a copy actually reaching a shelf at a price. Two of those have now happened for semaglutide outside the United States. None of the three has happened inside it, which is the constraint sitting above every figure in the annual cost article.
Canada: four companies, and a dose that is missing
Health Canada's Drug Product Database now lists semaglutide products from three companies other than Novo Nordisk. Dr Reddy's Laboratories has two semaglutide injection products recorded as marketed since May 6, 2026. Apotex has two, marketed since May 14, 2026, plus a third, Sevmia, approved on June 29, 2026 and not yet marketed. Aspen Pharmacare Canada has four, approved on July 17 and August 25, 2026, none of them yet marketed.[3]
Now the part that changes what those approvals mean for anyone reading this for weight-loss reasons. Every one of those products is a multidose prefilled pen that dispenses 0.25 mg or 0.5 mg doses, or 1 mg doses.[3] That is the strength range of the type 2 diabetes product. The 2.4 mg weight-management pen remains, in that same database, a Novo Nordisk product only. Canadian semaglutide has gone generic at the diabetes doses and has not gone generic at the obesity dose.
A 2026 Viewpoint in JAMA Internal Medicine examines this early Canadian entry specifically for what it implies for patients and policy in the United States,[1] and a 2026 analysis in the Canadian Journal of Cardiology works through what generic availability does to cost-effectiveness for guideline-indicated patients with type 2 diabetes in Canada.[2] Both are about diabetes populations, which follows directly from which doses went generic.
India: a launch date and a published monthly figure
India moved first. Dr Reddy's Laboratories announced, in a document filed with the United States Securities and Exchange Commission dated March 21, 2026, the launch of Obeda, described as India’s first semaglutide injection approved by the Drugs Controller General of India, indicated for type 2 diabetes. The announcement states the cost to the patient as INR 4,200 per month for both strengths.[4]
Same pattern. The first Indian generic approval named a diabetes indication, not a weight-management one. That is not a coincidence of timing: the diabetes product is the older registration everywhere, so it is the one whose protection lapses first and the one a generic application can reference.
Approved, marketed, and the gap between them
Health Canada records those two states separately, and the difference is not cosmetic. Of the nine non-Novo semaglutide entries in the database, four carry a status of Marketed with an original market date attached, and five carry a status of Approved with no market date at all. An approval is permission to sell; a market date is evidence that selling started. Counting the approvals gives nine products. Counting what the register records as reaching the market gives four.
That gap governs the price question rather than decorating it. Two companies other than the originator are shipping. A third holds four approvals it has not used, and one of the two that are shipping holds a fifth under a second brand name.[3] Nothing in a register says when an unused approval becomes a product on a shelf, or whether it ever does.
Why the diabetes dose always goes first
The pattern in both countries follows from sequence rather than strategy. Semaglutide was registered for type 2 diabetes years before it was registered for weight management, and patent terms run from filing. The earliest-expiring protection therefore attaches to the earliest registration, and a generic application has to reference a specific approved product at a specific strength. So the diabetes pen is the first thing that can be copied, and the higher weight-management strength sits behind its own later approvals and its own later claims.
For a reader, the consequence is narrow and worth stating plainly: the existence of cheap generic semaglutide somewhere in the world is not, by itself, evidence that a cheap version of the obesity dose exists anywhere. The two are different products with different registration dates.
The United States: December 5, 2031, and then a decade more
The FDA's Orange Book lists, for each approved product, the patents the sponsor has declared. For semaglutide the drug-substance patent is US 8,129,343, and its listed expiration is December 5, 2031. It is listed against all three approved applications: the Ozempic injection, the Wegovy injection and the oral tablets.[5]
A substance patent lapsing is not the end of the list. The same register carries later-expiring patents against those products, including three running to August 24, 2038 and one to February 17, 2041, alongside device and formulation claims in between.[5] Pediatric exclusivity periods are recorded separately and run into 2028 and 2029 depending on the product.[5] Whether a given later patent would actually block a particular generic is a question courts answer, not a question a register answers.
What the register does answer cleanly is the present state. Every semaglutide product listed in the Orange Book today is a new drug application held by Novo Nordisk. There is no approved abbreviated application — no generic semaglutide — in the United States.[5] That is the fact a US buyer is actually operating under, whatever a headline about Canada says.
A compounded preparation is not a generic
These two things are routinely conflated in marketing copy and they are not related. A generic is an approved product: a manufacturer demonstrates that its version is the same active ingredient at the same strength and is bioequivalent to the reference drug, and a regulator approves it, after which it is substitutable. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, efficacy or quality before they are dispensed. The full distinction is in the compounded-versus-brand article.
So a patent expiring in Ottawa or New Delhi does not make a compounded vial in Ohio into a generic, and it does not retroactively place one inside a regulatory review that never happened. The two routes to a lower price — an approved copy and an unapproved preparation — are different objects with different evidence behind them, and the cash-versus-coverage consequences of each are set out in the coverage article.
What a manufacturing floor does and does not tell you
One published estimate is worth knowing because it bounds the question from below. A 2024 economic evaluation modeled the cost of manufacturing diabetes medicines from active-ingredient shipment data, added formulation, operating costs, a profit margin and a tax allowance, and derived sustainable cost-based prices. For injectable semaglutide at 0.77 mg weekly it estimated $0.89 to $4.73 per month, against lowest current market prices of $38.21 to $353.74 across the countries surveyed.[6]
The oral form is the surprise. For oral semaglutide at 10.5 mg daily the same method estimated $38.62 to $72.49 per month — a floor roughly eight to eighty times higher than the injectable’s, because a tablet has to carry far more active ingredient to deliver a fraction of it.[6] Competition is not a single lever that falls evenly across formats, and the format comparison itself is in the oral-versus-injectable article.
A cost-based price is a modeled floor, not a forecast and not an offer. It says what a competitive market could in principle reach; it says nothing about what any particular market will charge, or when.
What is unknown
Several things, and they should be named rather than filled in. It is not known when, or whether, the 2.4 mg weight-management strength goes generic in Canada or India, because nothing in either register has approved one. It is not known what a United States generic would be priced at, because none exists and none can be approved while the listed patents and exclusivities stand. It is not known how the later listed patents will be resolved, because that is litigation rather than a date. And it is not known what any of this does to a cash telehealth price, which is set by a seller rather than by a patent office.
What is knowable now is the current bill, and it is knowable by arithmetic rather than by prediction. The cost calculator builds an annual figure from a quoted monthly rate and the terms attached to it. Any page that converts a patent date into a promise about what something will cost has moved from the register to a guess, and that is one of the patterns worth recognizing in the telehealth red flags article.